LRFN5 and OLFM4 in Methamphetamine-Induced Psychosis

Recruiting now

Conditions studied: Methamphetamine Use Disorder, Methamphetamine-induced Psychosis

In brief

This cross-sectional observational case-control study aimed to examined serum levels of leucine-rich repeat and fibronectin type III domain-containing protein 5 (LRFN5) and olfactomedin-4 (OLFM4) levels in methamphetamine use disorder (MUD), methamphetamine-induced psychotic disorder (MP), and healthy control (HC) groups. The study also aimed to assessed systemic inflammation using the Aggregate Index of Systemic Inflammation (AISI) and examined associations between biomarkers and clinical symptom severity, including Insight Assessment Scale (IAS) and Positive and Negative Syndrome Scale (PANSS) scores.

Key facts

Study ID
NCT07450027
Run by
Elazığ Mental Health and Diseases Hospital
People needed
120
Starts
2025-09-01
Expected to finish
2026-04-01
Last updated by the study team
2026-03-04

Who can join

Age: 18 and older, up to 49. Sex: male. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.